Gerasimou George P, Aggelopoulou Theodora C, Costa Durval C, Gotzamani-Psarrakou Anna
12nd Laboratory of Nuclear Medicine--AHEPA University Hospital, Thessaloniki, Greece.
Nucl Med Rev Cent East Eur. 2006;9(2):147-53.
In this article the role of molecular imaging with SPECT and PET in patients with movement disorders is reviewed. It is mentioned that SPECT and PET imaging with cocaine analogues ((123)I-beta-CIT,(123)I-FP-CIT, (18)F-DOPA), radioligands labeling the presynaptic dopamine transporters, is of value for the differentiation of patients with PD or Parkinson-plus syndromes with individuals with essential tremor. In addition the clinical impact of this procedure, the role of molecular imaging in the preclinical diagnosis and in the follow-up of patients with PD, as well as, in the differential diagnosis between Alzheimer's disease and Lewy-body dementia, is evaluated. Finally, the clinical impact of (123)I-IBZM-SPECT imaging, a radiopharmaceutical which labels the postsynaptic D(2) receptors and the discrimination between idiopathic PD and Parkinson-plus syndromes (multiple system atrophy, progressive supranuclear palsy and corticobasal ganglia degeneration), is mentioned.
本文综述了单光子发射计算机断层扫描（SPECT）和正电子发射断层扫描（PET）分子成像在运动障碍患者中的作用。文中提到，使用可卡因类似物（（123）I-β-CIT、（123）I-FP-CIT、（18）F-DOPA）进行SPECT和PET成像，这些放射性配体标记突触前多巴胺转运体，对于区分帕金森病（PD）或帕金森叠加综合征患者与特发性震颤患者具有重要价值。此外，还评估了该检查方法的临床影响、分子成像在PD患者临床前诊断和随访中的作用，以及在阿尔茨海默病和路易体痴呆鉴别诊断中的作用。最后，提到了（123）I-碘苄酰胺（IBZM）-SPECT成像的临床影响，这是一种标记突触后D（2）受体的放射性药物，以及特发性PD与帕金森叠加综合征（多系统萎缩、进行性核上性麻痹和皮质基底节变性）之间的鉴别。
